TxCell Strengthens its Board of Directors
Complete the form below to unlock access to ALL audio articles.
TxCell SA has announced that it has appointed Dr. David Solomon as an additional independent member of the board and Chair of the Remuneration and Nominations sub-committee of the board.
Dr. David Solomon has extensive experience as a CEO in a number of listed biotech companies as well as other companies involved in healthcare investing and pharmacology research. Dr. Solomon is currently the President and CEO of Bionor, a NASDAQ OMX Oslo listed therapeutic vaccine company based in Oslo, Norway, with other offices in Copenhagen, Denmark, and New York, US.
“TxCell is delighted to further strengthen the board with the appointment of Dr. David Solomon. David will add to TxCell a considerable depth of experience across the biotech and healthcare investing sectors gained in both Europe and the US,” said François Meyer, Executive Chairman, TxCell. “TxCell’s development of Ovasave®, its lead personalized T-cell immunotherapy in refractory Crohn’s disease and Col-Treg, its second product candidate from the ASTrIA product platform for the treatment of autoimmune uveitis, benefits from a board with an enviable set of specialist skills, experience and expertise.”
Prior to joining Bionor, Dr. Solomon was CEO of Zealand Pharma A/S from 2008 to 2015. From 2003 to 2006 he headed healthcare investing at Carrot Capital Healthcare Ventures in New York, US. Dr. Solomon has held several leadership positions at a number of biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals, Critical Diagnostics and Vital Sensors. In addition, he is currently on the boards of Onxeo in Paris (Euronext and NASDAQ OMX) and Promosome, in La Jolla, CA, US.
Dr. Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York where he received his doctorate in 1991. Dr. Solomon has served as a faculty member at Columbia University’s College of Physicians and Surgeons.
“TxCell’s innovative personalized T-cell immunotherapies are at the forefront of one of the most exciting new areas in medicine. TxCell’s approach has the potential to create life-changing therapies for patients suffering from a range of severe chronic and refractory autoimmune inflammatory diseases,” said David Solomon. “I am delighted to join the Board of TxCell and to be able to bring my experience to support the development of TxCell and its potentially life-changing therapies.”